Precipio (NASDAQ:PRPO – Get Free Report) and Mitesco (OTCMKTS:MITI – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, institutional ownership, dividends and analyst recommendations.
Earnings & Valuation
This table compares Precipio and Mitesco”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Precipio | $24.05 million | 1.71 | -$360,000.00 | ($0.47) | -48.85 |
| Mitesco | $40,000.00 | 31.93 | $500,000.00 | ($0.33) | -0.18 |
Profitability
This table compares Precipio and Mitesco’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Precipio | -3.57% | -6.73% | -4.49% |
| Mitesco | -7,638.20% | -2.18% | -2,982.65% |
Insider and Institutional Ownership
10.5% of Precipio shares are held by institutional investors. Comparatively, 0.0% of Mitesco shares are held by institutional investors. 16.6% of Precipio shares are held by company insiders. Comparatively, 4.9% of Mitesco shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings for Precipio and Mitesco, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Precipio | 1 | 0 | 0 | 0 | 1.00 |
| Mitesco | 0 | 0 | 0 | 0 | 0.00 |
Volatility and Risk
Precipio has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Mitesco has a beta of 4.88, meaning that its share price is 388% more volatile than the S&P 500.
About Precipio
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.
About Mitesco
Mitesco, Inc. does not have significant operations. Previously, it was engaged in healthcare technology and services business. Mitesco, Inc. is based in Vero Beach, Florida.
Receive News & Ratings for Precipio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precipio and related companies with MarketBeat.com's FREE daily email newsletter.
